SCHEMBL223652

SCHEMBL223652

CCCCC[C@H]1CC[C@H](c2ccc(-c3ccc(OC)cc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.50
CYP2C9 P11712 1/20 0.43
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 2/20 0.41
MAPK1 P28482 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
SPHK1 Q9NYA1 3/20 0.40
GAA P10253 1/20 0.40
DGAT1 O75907 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRM2 Q14416 1/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222090 1.00 DRD2 (0.50) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11282229 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11279457 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11283921 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11287630 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11283709 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL10659015 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11286368 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL21321779 0.99 DRD2 (0.49) DRD2CYP2C9MAPTALDH1A1MEN1
SCHEMBL11281659 0.96 DRD2 (0.51) DRD2CYP2C9MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122269-B Ultraviolet light absorber 光学转变公司 2024-05-28 CN disclosed
CN-113122269-A Ultraviolet light absorber 光学转变公司 2021-07-16 CN disclosed
CN-107109227-B Ultraviolet light absorber 光学转变公司 2021-05-04 CN disclosed
US-10619098-B2 Ultraviolet light absorbers TRANSITIONS OPTICAL, INC. (US) 2020-04-14 US disclosed
EP-3201292-B1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL INC (US) 2018-08-01 EP disclosed
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL, INC. 2017-09-28 US disclosed
EP-3201292-A1 ULTRAVIOLET LIGHT ABSORBERS Transitions Optical, Inc. (US) 2017-08-09 EP disclosed
EP-2698413-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2016-12-28 EP disclosed
EP-2698412-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2016-10-12 EP disclosed
WO-2016053662-A1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL, INC. (US) 2016-04-07 WO disclosed
EP-2698413-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
EP-2698412-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
WO-2013022605-A1 MESOGENIC STABILIZERS TRANSITIONS OPTICAL, INC. (US) 2013-02-14 WO disclosed
US-8349210-B2 Mesogenic stabilizers TRANSITIONS OPTICAL, INC. (US) 2013-01-08 US disclosed
US-20120003401-A1 MESOGENIC STABILIZERS TRANSITIONS OPTICAL, INC. (US) 2012-01-05 US disclosed
EP-2303987-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2011-04-06 EP disclosed
US-7910019-B2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2011-03-22 US disclosed
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
WO-2009158483-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10619098-B2 Ultraviolet light absorbers ERCC1, MCM4, ERCC4 DRD2 1763/4885CYP2C9 484/4885MAPT 80/4885
US-20120003401-A1 MESOGENIC STABILIZERS PYM1, BMI1, C1S DRD2 224/4885CYP2C9 4629/4885MAPT 1853/4885
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS MCM4, ERCC1, ERCC4 DRD2 2060/4885CYP2C9 729/4885MAPT 85/4885
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG DRD2 883/4885CYP2C9 2891/4885MAPT 2243/4885
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG DRD2 883/4885CYP2C9 2891/4885MAPT 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.